Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 45 )

2018 ( 1018 )

2017 ( 990 )

2016 ( 992 )

Custom range...

Search Results: 1 - 10 of 92256 matches for " Fu-Chen Kuo "
All listed articles are free for downloading (OA Articles)
Page 1 /92256
Display every page Item
Upregulation of Salmonella-Induced IL-6 Production in Caco-2 Cells by PJ-34, PARP-1 Inhibitor: Involvement of PI3K, p38 MAPK, ERK, JNK, and NF- B
Fu-Chen Huang
Mediators of Inflammation , 2009, DOI: 10.1155/2009/103890
Abstract: Following Salmonella invasion, intestinal epithelial cells release a distinct array of proinflammatory cytokines. Interleukin (IL)-6 produced by enterocytes may have anti-inflammatory and cell-protective effects, and may counteract some of the injurious effects of sepsis and endotoxemia. Recent studies in a variety of rodent models of experimental colitis by using PJ-34, a potent poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, support the concept that the marked beneficial effect of PJ-34 can be exploited to treat human inflammatory diseases. The present study was to investigate the effect of PJ-34 on Salmonella-induced enterocyte IL-6 production and its mechanisms. We found that PJ-34 enhanced Salmonella-induced IL-6 production in Caco-2 cells, either secreted protein or mRNA expression. PJ-34 treatment enhanced the activity of NF-B in Salmonella-infected Caco-2 cells. Besides, the involvement of PJ-34 in up-regulating IL-6 production in S. typhimurium-infected Caco-2 cells might be also through the ERK but not p38 MAPK, JNK or PI3K/Akt pathways, as demonstrated by Western blot of phosphorylated ERK, p38, JNK and Akt proteins. It suggests that PJ-34 may exert its protective effect on intestinal epithelial cells against invasive Salmonella infection by up-regulating IL-6 production through ERK and NF-B but not P38 MAPK, JNK or PI3K/Akt signal pathways.
Diaquabis(tetrazolo[1,5-a]pyridine-8-carboxylato-κ2N1,O)cobalt(II) dihydrate
Min Xue,Fu-Chen Liu
Acta Crystallographica Section E , 2009, DOI: 10.1107/s1600536809019187
Abstract: In the title compound, [Co(C6H3N4O2)2(H2O)2]·2H2O, the CoII atom is located on an inversion center in a slightly distorted octahedral environment formed by the O atoms of two water molecules, and the N and O atoms of the chelating tetrazolo[1,5-a]pyridine-8-carboxylate anions. Hydrogen bonds of the O—H...O and O—H...N types result in a three-dimensional supramolecular network.
Fu-Chen Liu,Jie Ouyang
Acta Crystallographica Section E , 2008, DOI: 10.1107/s1600536807061569
Abstract: In the crystal structure of the title compound, [Cu2(N3)2(C10H8N2)]n, each CuI atom is coordinated by two symmetry-related azide anions and 4,4′-bipyridine (bipy) ligands in a strongly distorted tetrahedral geometry. The Cu atom and the azide anion occupy general positions while the bipy molecule is located on a centre of inversion. Each two symmetry-related copper(I) cations and two symmetry-related azide anions form dimers, which are additionally connected by the anions into layers. These layers are linked by the 4,4′-bipyridine ligands into a three-dimensional coordination network.
The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012
Chao-Hung Kuo,Fu-Chen Kuo,Huang-Ming Hu,Chung-Jung Liu,Sophie S. W. Wang,Yen-Hsu Chen,Ming-Chia Hsieh,Ming-Feng Hou,Deng-Chyang Wu
Gastroenterology Research and Practice , 2012, DOI: 10.1155/2012/168361
Abstract: This paper reviews the literature about first-line therapies for H. pylori infection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance. 1. Introduction Eradicating Helicobacter pylori (H. pylori) is the most important aspect of managing H. pylori-related gastrointestinal diseases. In the past decade, the Maastricht III Consensus Report has recommended that proton pump inhibitor- (PPI-) clarithromycin-amoxicillin or metronidazole treatment is the first choice for H. pylori infection [1]. Although some studies have revealed that the eradication rates of standard triple therapies are around 80% (by per-protocol (PP) analysis) [2, 3], most studies have demonstrated the success rate of recommended triple therapies is falling [4–7]. According to recent studies, such eradication rates have plummeted to even 25%–60% [8–10]. The many causes of fall in efficacy are varied including antibiotic resistance, poor compliance, high gastric acidity, high bacterial load, and the cytochrome P450 2C19 (CYP2C19) polymorphism [10]. Compliance is an important factor where patients with good compliance (taking more than 60% of prescribed agents) have a higher treatment success compared to patients with poor compliance (96 versus 69%) [11]. The factors that negatively affect successful eradication are an increase in body mass index and smoking [12, 13]. Besides, other factors including the patient’s history of antibiotic use, the cost, and availability of the drugs would also influence the choice of regimen. In order to overcome the challenge of decreasing eradication rates, many novel first-line therapies have been developed. According to guidelines of the Maastricht III, the minimal acceptable eradication level recommended
Current Pharmacological Management of Gastroesophageal Reflux Disease
Yao-Kuang Wang,Wen-Hung Hsu,Sophie S. W. Wang,Chien-Yu Lu,Fu-Chen Kuo,Yu-Chung Su,Sheau-Fang Yang,Chiao-Yun Chen,Deng-Chyang Wu,Chao-Hung Kuo
Gastroenterology Research and Practice , 2013, DOI: 10.1155/2013/983653
Abstract: Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for GERD. Although proton pump inhibitor is the most potent acid suppressant and provides good efficacy in esophagitis healing and symptom relief, about one-third of patients with GERD still have persistent symptoms with poor response to standard dose PPI. Antacids, alginate, histamine type-2 receptor antagonists, and prokinetic agents are usually used as add-on therapy to PPI in clinical practice. Development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophageal hypersensitivity. Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment. 1. Introduction Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder in the general population, and its prevalence is increasing worldwide [1]. According to the Montreal definition, GERD is diagnosed when the reflux of stomach contents causes troublesome symptoms and/or complications [2], and it is the most common outpatient gastrointestinal disease diagnosed in USA [3]. Reflux from stomach causes symptoms like heartburn and regurgitation, which are the cardinal symptoms of GERD, and other symptoms, such as chest pain, asthma, hoarseness, and sleep disturbance, are also considered as atypical or extraesophageal symptoms of GERD [4]. Troublesome symptoms of GERD have adverse impact on health-related quality of life (HRQL) [5], and patients with more frequent or more severe symptoms have lower HRQL, work productivity, and sleep quality [5, 6]. Chronic reflux is also an important risk factor of esophageal adenocarcinoma [7]. There are many factors contributing to GERD, including transient lower esophageal sphincter relaxation (TLESR), reduced LES pressure, impaired esophageal mucosal defense, poor esophageal clearance, visceral hypersensitivity, hiatal hernia, and delayed gastric emptying, and TLESRs is the predominant mechanism of reflux formation [8]. Obesity is an independent risk factor for development of GERD and is also associated with its complications,
Eradication of Helicobacter pylori Is Associated with the Progression of Dementia: A Population-Based Study
Yang-Pei Chang,Guei-Fen Chiu,Fu-Chen Kuo,Chiou-Lian Lai,Yuan-Han Yang,Huang-Ming Hu,Pi-Yu Chang,Chiao-Yun Chen,Deng-Chyang Wu,Fang-Jung Yu
Gastroenterology Research and Practice , 2013, DOI: 10.1155/2013/175729
Abstract: Objective. To evaluate the effect of eradication of Helicobacter pylori (H. pylori) on the progression of dementia in Alzheimer’s disease (AD) patients with peptic ulcer. Methods. Participants with the diagnosis of AD and peptic ulcer were recruited between 2001 and 2008. We examined the association between eradication of H. pylori and the progression of AD using the multiple regression models. Medication shift from Donepezil, Rivastgmine, and Galantamine to Mematine is defined as progression of dementia according to the insurance of National Health Insurance (NHI) under expert review. Results. Among the 30142 AD patients with peptic ulcers, the ratio of medication shift in AD patients with peptic ulcers is 79.95%. There were significant lower incidence comorbidities (diabetes mellitus, hypertension, cerebrovascular disease, coronary artery disease, congestive heart failure and hyperlipidemia) in patients with H. pylori eradication as compared with no H. pylori eradication. Eradication of H. pylori was associated with a decreased risk of AD progression (odds ratio [OR] 0.35 [0.23–0.52]) as compared with no H. pylori eradication, which was not modified by comorbidities. Conclusions. Eradication of H. pylori was associated with a decreased progression of dementia as compared to no eradication of H. pylori in AD patients with peptic ulcers. 1. Introduction Alzheimer’s disease (AD) is a common neurodegenerative disorder for which causes are diverse, and it involves similar neuroinflammation cascade as prion disease [1]. Cerebral amyloid deposits are colocalized with a broad variety of inflammation-related proteins (complement factors, acute-phase protein, and proinflammatory cytokines) and clusters of activated microglia [2]. Currently, identified risk factors of AD include age, sex, plasma homocysteine level, and genetic factors like apolipoprotein E allele ε4 [3, 4]. Several studies have shown the association between infection and AD, including HSV-1, Chlamydia pneumonia, spirochetes, and Helicobacter pylori (H. pylori) [5–8]. As for H. pylori infection, previous case-control studies found an association between H. pylori and AD. An impressive intervention study has shown positive results that the H. pylori eradication may improve the cognitive functiona outcome within two years, but the sample size of case (28 patients) and controls (16 patients) might be small for application to general population [9]. Additionally, some agents like statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have also shown to potentially attenuate
Postural Adaptations To Supra-postural Tasks in Children With Developmental Coordination Disorder
Chen Fu-Chen,Stoffregen Thomas A,Wade Michael G.
BIO Web of Conferences , 2011, DOI: 10.1051/bioconf/20110100015
Abstract: We investigated the effect of varying memory (cognitive) demands, and visual (perceptual) demands on postural motion. Sixty four children (32 DCD, 32 TDC, 9-to-10 years) were volunteers. Each performed separate memory and visual tasks at two levels of difficulty; easy (LD) and hard (HD) while recording their postural motion. For the memory task, both groups reduced postural sway in the HD condition. For the visual task only the TDC group reduced postural sway in the HD condition; DCD children did not. The DCD group did not reduce postural motion but, in fact, increased motion. We also found several group task interactions on sway. Our data suggest a weakening of the action linkage between both cognitive and perceptual tasks in children diagnosed with movement difficulties. The data are discussed in the context of limitations in the embodied relationship between posture and both perceptual and cognitive activity.
Jiong-Peng Zhao,Fu-Chen Liu
Acta Crystallographica Section E , 2010, DOI: 10.1107/s1600536810023810
Abstract: The asymmetric unit of the title compound, [Co(C6H12NO4)2], contains one half-molecule with the CoII ion situated on an inversion center. Intermolecular O—H...O hydrogen bonds generate a three-dimensional hydrogen-bonding network, which consolidates the crystal packing.
Jiong-Peng Zhao,Fu-Chen Liu
Acta Crystallographica Section E , 2010, DOI: 10.1107/s1600536810027029
Abstract: In the crystal structure of the title compound, [Ag(C7H3N2O2S)]n, the AgI atom is coordinated by two N atoms and three O atoms of four organic ligands forming a distorted square pyramid. The carboxylate group acts as a bidentate ligand on one AgI atom and as a bridging group for a symmetry-related AgI atom, forming a dimer. Futhermore, the two N atoms of two thiadiazole rings bridge a third symmetry-related AgI atom, forming a six-membered ring. These two frameworks, AgO2Ag and AgN4Ag, extend in three directions, forming a three-dimensionnal polymer. The whole polymer is organized around inversion centers.
Jiong-Peng Zhao,Fu-Chen Liu
Acta Crystallographica Section E , 2010, DOI: 10.1107/s1600536810027030
Abstract: In the title compound, [Cu3(C5H3N2O2)2(N3)4]n, one of the CuII atoms lies on an inversion centre and is octahedrally coordinated by two bidentate chelating pyrimidine-2-carboxylate ligands and two azide anions, each of which gives an N:N-bridge to the second inversion-related CuII centre in the formula unit. The second CuII atom is five-coordinated with a distorted square-pyramidal coordination sphere comprising a single bidentate chelating pyrimidine-2-carboxylate anion and three azide N anions, two of which doubly bridge centrosymmetric CuII centres, giving a two-dimensional network structure extending parallel to (010).
Page 1 /92256
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.